CD BioGlyco is a leading global biology company, and we are committed to providing the most comprehensive and high-quality one-stop customized services in the field of cancer glucose metabolism.
Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM) is a dedicated cancer glucose metabolism profiling platform. Based on multi-omics technologies such as genomics, proteomics, and metabolomics, it provides quantitative analysis and functional analysis of glucose metabolites at the cell, tissue, and animal levels during the whole process of cancer progression, metabolic enzyme expression and activity detection, and glucose metabolism, flux analysis. We expect to provide a full range of services for cancer glucose metabolism research and promote the application of cancer glucose metabolism research in the fields of cancer prevention, diagnosis and treatment.
We provide comprehensive services covering genomics, metabolomics, proteomics, and metabolic fluxomics.
A multi-omics platform dedicated to providing cancer glucose metabolism research services.
We provide personalized service based on the customers' research priorities.
Leveraging four unique cancer omics technology to change the paradigm of cancer glucose metabolism research.
Guide cancer research with multi-omics data on cancer glucose metabolism, and find the intervention method of glucose metabolism to cure cancer.
If you are interested in our services, please contact us for more detailed information.
